This webinar presentation will provide cutting edge researchers who need to process peripheral blood an overview of this new system’s underlying technology, capabilities and performance.
TORONTO (PRWEB)
April 30, 2020
The critical upstream processes of cell sorting and concentration have remained largely unchanged for decades. Researchers have relied on permutations of the 100-year-old centrifuge, 50-year-old density gradient media, or 30-year-old bead approach. While one can manipulate speeds, antibodies and concentrations, the underlying limitations of manual handling, e.g. excessive cell manipulation, labor-intensiveness and performance inconsistency have persisted.
At the same time, as today’s cell and gene-driven research environments are increasingly dependent on downstream highly sophisticated (and high-priced) analytical tools such as mass cytometry and single-cell profiling, upstream sample preparation has taken on critical significance. Sensitivity to red blood cell, platelet and reagent contamination have only increased and reliance on artificial cell populations such as PBMCs, which lack the influential granulocyte component, limit our understanding of in vivo biology.
In mass-cytometry and flow cytometry, significant contaminants can decrease the ability to capture critical target events. Furthermore, scRNA sequencing, a high cost analysis, also benefits from low impurities. The calls for a more stable, time-efficient, reliable, high-yield, automated cell processing solution for sample preparation have only grown louder.
In response to this need, MicroMedicine has developed a novel, microfluidics-based system for cell differentiation, selection and concentration. This innovative approach, called SorterraTM, is a label-free, automated, easy-to-use and train system, which does not involve centrifugation. As a result, Sorterra offers improvements in dedicated labor time, cell yield and purity, consistency, and reliability.
This webinar presentation will provide cutting edge researchers who need to process peripheral blood an overview of this new system’s underlying technology, capabilities and performance.
Join Melanie Scully, PhD, Applications Team Lead, MicroMedicine and Nirav “Rav” Sheth, VP, Commercial Development, MicroMedicine in a live webinar on Friday, May 15, 2020 at 12pm EDT (5pm BST/UK).
For more information or to register for this event, visit Improving Peripheral Blood Processing – Introducing a Novel, Automated Alternative to Reagents and Centrifugation.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
ABOUT MICROMEDICINE
MicroMedicine, Inc., is a life sciences company with an innovative and proven microfluidics platform for high-volume processing of biological fluids for the purposes of research and clinical applications. Founded at Massachusetts General Hospital in 2015, MicroMedicine is committed to transforming research, clinical diagnostics, and cell therapy with novel innovations. The patented microfluidic platform can be utilized for multiple applications, including cell isolation, cell concentration, and fluid exchange. The company resides in the heart of Boston’s life sciences ecosystem in Waltham, Massachusetts, USA. For more information about MicroMedicine, Inc., please call 617-744-1918 or visit micromedicine.com.
To learn more about MicroMedicine visit micromedicine.com
Contact:
Rav Sheth
Email: rav@micromedicine.com
Share article on social media or email: